Bavarian Nordic EVP on Covid-19 vaccine: "We couldn't have wished for better data"
On Sunday, Bavarian Nordic unveiled data from its phase II study of its Covid-19 vaccine, ABNCoV2. According to Bavarian Nordic's EVP & CIO, the data was the best-case scenario.
by marketwire, translated by daniel pedersen
Phase II data from Bavarian Nordic's Covid-19 vaccine, ABNCoV2, compares well with known mRNA vaccines from Pfizer/Biontech and US-based Moderna, Executive Vice President and Chief Financial Officer Henrik Juuel tells MarketWire in an interview.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Bavarian Nordic: We can adapt our vaccine if necessary
For subscribers
